Eye Center, Sanno Hospital, Tokyo, Japan.
PLoS One. 2020 Nov 4;15(11):e0241814. doi: 10.1371/journal.pone.0241814. eCollection 2020.
This study aimed to examine clinical results in low-vault eyes after implementation of a Hole implantable collamer lens (KS-AquaPORT™, STAAR Surgical Company) in terms of visual outcomes and complications over a one-year follow-up period. This was a retrospective cohort study of subjects who underwent Hole implantable collamer lens surgery at Sanno Hospital, exhibited low vault, and were followed up for 1 year. Patients were included if they met the following criteria: 20≤ age ≤55 years; stable refraction ≥6 months; -1.0 to -20.0 diopters of myopia; endothelial cell density ≥1800 cells/mm2; and no history of ocular surgery, progressive corneal degeneration, cataract, glaucoma, or uveitis. Main outcome measurements were the safety and efficacy indices, predictability, and vault. Values were indicated as the mean ± standard deviation. Subjects included 16 patients (age: 38 ± 8 years; 6 males; 25 eyes). Toric lenses were utilized for 10 eyes. Implantable collamer lens size was 12.1, 12.6, and 13.2 mm for 18, 6, and 1 eye(s), respectively. One year postoperatively, the safety index was 1.07; for 22 eyes with a target refraction of that of emmetropic eyes, the efficacy index was 0.90; and 96% of eyes were within ± 0.50 diopters of attempted versus achieved spherical equivalent correction. Postoperative vault was 142 ± 60 μm. One year postoperatively, no additional surgery was required for rotation of toric implantable collamer lens, and no advanced cataracts, increased intraocular pressure, or decreased endothelial cells were observed. In conclusion, Hole implantable collamer lens yielded satisfactory visual outcomes and no postoperative complications for low-vault eyes, suggesting its suitability for such cases.
本研究旨在探讨 Hole 可植入 Collamer 透镜（KS-AquaPORT ™，STAAR Surgical Company）在低拱顶眼中的临床效果，包括术后 1 年的视觉效果和并发症。这是一项回顾性队列研究，研究对象在 Sanno 医院接受 Hole 可植入 Collamer 透镜手术，表现为低拱顶，并随访 1 年。符合以下标准的患者纳入研究：年龄 20≤55 岁；稳定的屈光状态≥6 个月；近视-1.0 至-20.0 屈光度；内皮细胞密度≥1800 个细胞/mm2；无眼部手术史、进行性角膜变性、白内障、青光眼或葡萄膜炎。主要观察指标为安全性和有效性指标、可预测性和拱顶。数值表示为平均值±标准差。共纳入 16 例患者（年龄：38±8 岁；6 例男性；25 只眼）。10 只眼使用了散光透镜。植入式 Collamer 透镜的尺寸分别为 12.1、12.6 和 13.2mm，适用于 18、6 和 1 只眼。术后 1 年，安全性指数为 1.07；对于 22 只目标屈光度为正视眼的眼，有效性指数为 0.90；96%的眼屈光度在±0.50 屈光度的目标等效球镜矫正范围内。术后拱顶高度为 142±60μm。术后 1 年，无需再次手术矫正散光植入式 Collamer 透镜的旋转，未发现进展性白内障、眼内压升高或内皮细胞减少。综上所述，Hole 可植入 Collamer 透镜治疗低拱顶眼可获得满意的视觉效果，且无术后并发症，提示其适用于此类病例。
